Document 0230
 DOCN  M9440230
 TI    Management of acyclovir-resistant herpes simplex and varicella-zoster
       virus infections.
 DT    9404
 AU    Balfour HH Jr; Benson C; Braun J; Cassens B; Erice A; Friedman-Kien A;
       Klein T; Polsky B; Safrin S; Department of Laboratory Medicine &
       Pathology, University of; Minnesota Health Sciences Center, Minneapolis.
 SO    J Acquir Immune Defic Syndr. 1994 Mar;7(3):254-60. Unique Identifier :
       AIDSLINE MED/94149559
 AB    Persons with AIDS who have CD4+ counts < or = 100 and transplant
       patients, especially bone marrow allograft recipients, may experience
       clinically significant infections with acyclovir-resistant herpes
       simplex virus (HSV) or varicella-zoster virus (VZV). Patients who have
       received prior repeated acyclovir treatment appear to be at the highest
       risk of harboring acyclovir-resistant strains. Algorithms for the
       management of these infections were developed at a recent roundtable
       symposium. The consensus of the panelists was that treatment with
       foscarnet should be initiated within 7-10 days in patients suspected to
       have acyclovir-resistant HSV or VZV infections. Foscarnet therapy should
       be continued for at least 10 days or until lesions are completely
       healed.
 DE    Acquired Immunodeficiency Syndrome/COMPLICATIONS
       Acyclovir/*PHARMACOLOGY/THERAPEUTIC USE  Adult  Algorithms  Case Report
       Drug Resistance, Microbial  Female  Foscarnet/*THERAPEUTIC USE  Herpes
       Simplex/DRUG THERAPY/MICROBIOLOGY  Herpes Zoster/DRUG
       THERAPY/MICROBIOLOGY  Herpesviridae Infections/*DRUG
       THERAPY/MICROBIOLOGY  Herpesvirus 3, Human/*DRUG EFFECTS  Human
       Immunocompromised Host  Male  Recurrence  Simplexvirus/*DRUG EFFECTS
       Support, Non-U.S. Gov't  Trifluridine/THERAPEUTIC USE
       Vidarabine/THERAPEUTIC USE  CONSENSUS DEVELOPMENT CONFERENCE  JOURNAL
       ARTICLE  REVIEW

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).